Eculizumab as a promising treatment in thymoma-associated myasthenia gravis
Myasthenia gravis is a chronic autoimmune disorder caused by antibodies directed against the neuromuscular junction. Some patients may have an associated thymoma, which confers a worse prognosis. Eculizumab, a monoclonal antibody that inhibits the activation of terminal complement, has recently been...
Main Authors: | Valentina Vélez-Santamaría, Velina Nedkova, Laura Díez, Christian Homedes, M. Antonia Alberti, Carlos Casasnovas |
---|---|
Format: | Article |
Language: | English |
Published: |
SAGE Publishing
2020-06-01
|
Series: | Therapeutic Advances in Neurological Disorders |
Online Access: | https://doi.org/10.1177/1756286420932035 |
Similar Items
-
Intravenous immunoglobulins may prevent prednisone-exacerbation in myasthenia gravis
by: Laura Díez-Porras, et al.
Published: (2020-08-01) -
Myasthenia gravis exacerbation after melatonin administration: case series from a tertiary referral centre
by: Velina Nedkova-Hristova, et al.
Published: (2020-11-01) -
Multiple Thymoma with Myasthenia Gravis
by: Dong Hyun Seo, et al.
Published: (2017-02-01) -
Thymoma with Myasthenia Gravis in Adolescent
by: Prasad K Shetty,, et al.
Published: (2011-01-01) -
Autoimmunity in thymoma-associated Myasthenia gravis
by: Buckley, Camilla
Published: (2001)